BioAxone BioSciences
BioAxone is a biopharmaceutical company dedicated to developing transformative treatments for neurotrauma and neurovascular disorders. With over 20 years of research, the company focuses on axon regeneration and neuronal signaling pathways, aiming to restore neurological function and reduce disability in patients with spinal cord injuries and related conditions.
Industries
Nr. of Employees
small (1-50)
BioAxone BioSciences
Patents
Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US-11701366-B2
View DetailsTreatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US-10857157-B2
View Details
Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US-11701366-B2
View DetailsTreatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US-10857157-B2
View DetailsProducts
BA-210 (Rho pathway inhibitor)
Clinical-stage Rho pathway inhibitor developed to promote axon regeneration and provide neuroprotective effects after acute spinal cord injury; subject of Phase IIb/III clinical development history and available for licensing.
BA-434 (sdRNA targeting PTEN)
Preclinical self-delivering RNA interference therapeutic designed to transiently suppress PTEN in adult neurons to overcome intrinsic barriers to axon regeneration.
BA-1049 (ROCK2-selective small molecule)
Small molecule ROCK2-selective kinase inhibitor developed to restore endothelial barrier function and treat neurovascular disorders including cerebral cavernous malformation and ischemic reperfusion injury.
Biologic Rho inhibitor (licensed development candidates)
Biologic-format Rho pathway inhibitors developed for acute spinal cord injury and related neurotrauma indications; previously advanced into clinical testing and subject to licensing arrangements.
BA-210 (Rho pathway inhibitor)
Clinical-stage Rho pathway inhibitor developed to promote axon regeneration and provide neuroprotective effects after acute spinal cord injury; subject of Phase IIb/III clinical development history and available for licensing.
BA-434 (sdRNA targeting PTEN)
Preclinical self-delivering RNA interference therapeutic designed to transiently suppress PTEN in adult neurons to overcome intrinsic barriers to axon regeneration.
BA-1049 (ROCK2-selective small molecule)
Small molecule ROCK2-selective kinase inhibitor developed to restore endothelial barrier function and treat neurovascular disorders including cerebral cavernous malformation and ischemic reperfusion injury.
Biologic Rho inhibitor (licensed development candidates)
Biologic-format Rho pathway inhibitors developed for acute spinal cord injury and related neurotrauma indications; previously advanced into clinical testing and subject to licensing arrangements.
Services
Licensing of preclinical and clinical-stage drug candidates to commercial partners for further development and commercialization.
Support for preclinical IND-enabling studies, regulatory package preparation, and coordination with clinical and manufacturing partners.
Licensing of preclinical and clinical-stage drug candidates to commercial partners for further development and commercialization.
Support for preclinical IND-enabling studies, regulatory package preparation, and coordination with clinical and manufacturing partners.
Expertise Areas
- Clinical trial management for CNS indications
- Neurotrauma therapeutics development
- Neurovascular drug development
- Preclinical translational research
Key Technologies
- Rho pathway modulation
- ROCK2-selective kinase inhibition
- Self-delivering RNA interference (sdRNA)
- Biologic Rho inhibitors
News & Updates
Upcoming scientific conferences on spinal cord injury. Access site.
Information on cerebral cavernous malformation. Access site.
An article published in Volume 44, Issue 11 of _Journal of Cerebral Blood Flow & Metabolism_ discusses preclinical data showing NRL-1049 as a promising drug candidate to preserve the blood-brain barrier after brain injury.
BioAxone's drug candidate BA-1049, a ROCK2 inhibitor, targets the cause of CCM, a genetic disease with no current pharmacological treatment, potentially transforming the management of this condition.
BioAxone announced the issuance of a patent for pharmaceutical compositions of BA-210, a drug candidate for treating spinal cord injury.
Publication in _Journal of Cerebral Blood Flow & Metabolism_ highlighting NRL-1049 as a promising drug candidate.
Upcoming scientific conferences on spinal cord injury. Access site.
Information on cerebral cavernous malformation. Access site.
An article published in Volume 44, Issue 11 of _Journal of Cerebral Blood Flow & Metabolism_ discusses preclinical data showing NRL-1049 as a promising drug candidate to preserve the blood-brain barrier after brain injury.
BioAxone's drug candidate BA-1049, a ROCK2 inhibitor, targets the cause of CCM, a genetic disease with no current pharmacological treatment, potentially transforming the management of this condition.
BioAxone announced the issuance of a patent for pharmaceutical compositions of BA-210, a drug candidate for treating spinal cord injury.
Publication in _Journal of Cerebral Blood Flow & Metabolism_ highlighting NRL-1049 as a promising drug candidate.